154 related articles for article (PubMed ID: 25651426)
1. Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials.
Marton A; Kezouh A; Petrogiannis-Haliotis T; Assouline S
Leuk Lymphoma; 2015; 56(9):2747-9. PubMed ID: 25651426
[No Abstract] [Full Text] [Related]
2. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
[No Abstract] [Full Text] [Related]
3. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
4. Polymyositis following autologous haematopoietic stem cell transplantation.
Hedermann G; Marquart HV; Vissing J
Scand J Rheumatol; 2016 Oct; 45(5):429-31. PubMed ID: 27050436
[No Abstract] [Full Text] [Related]
5. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
6. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
7. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Hu K; Gao JJ; Li QH; Tian L; Wan W; Zhao W; Wang JJ; Fu L
Kaohsiung J Med Sci; 2019 Jul; 35(7):425-431. PubMed ID: 31050117
[TBL] [Abstract][Full Text] [Related]
8. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
9. Testicular lymphoma.
Thomas LC; Adonizio C; Filicko-O'Hara J; Golshayan AR; Costa LJ; Morris GJ
Semin Oncol; 2010 Dec; 37(6):549-54. PubMed ID: 21167372
[No Abstract] [Full Text] [Related]
10. Primary ovarian lymphoma--a rare entity.
Afshan A; Sadaf N
J Pak Med Assoc; 2013 Apr; 63(4):519-20. PubMed ID: 23905454
[TBL] [Abstract][Full Text] [Related]
11. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
Camus V; Tilly H
Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
Cascione L; Rinaldi A; Chiappella A; Kwee I; Ciccone G; Altenbuchinger M; Kohler C; Vitolo U; Inghirami G; Bertoni F
Br J Haematol; 2018 Aug; 182(3):453-456. PubMed ID: 28737236
[No Abstract] [Full Text] [Related]
13. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
[No Abstract] [Full Text] [Related]
14. [Initial treatment of diffuse large B-cell lymphoma].
Kinoshita T
Nihon Rinsho; 2012 Apr; 70 Suppl 2():503-8. PubMed ID: 23134006
[No Abstract] [Full Text] [Related]
15. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Leuk Lymphoma; 2017 Mar; 58(3):736-739. PubMed ID: 27686739
[No Abstract] [Full Text] [Related]
16. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
17. Intravascular large B-cell lymphoma--a diagnostic dilemma.
Ramkumar B; Hutchison R; Khadim H; Gajra A
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e18-21. PubMed ID: 24060286
[No Abstract] [Full Text] [Related]
18. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
[TBL] [Abstract][Full Text] [Related]
19. A blind skin biopsy diagnosing an intravascular large B-cell lymphoma.
Deschamps L; Signate A; Delaunay C; Morales I; Warter A; Smadja D; Derancourt C
Eur J Dermatol; 2011; 21(1):114-5. PubMed ID: 21233067
[No Abstract] [Full Text] [Related]
20. Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.
Brito ABC; Delamain MT; de Oliveira C; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Silvia Passos Lima C
Br J Haematol; 2017 May; 177(4):650-654. PubMed ID: 27098707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
